Particles that are 10-times smaller than meloxicam’s (Mobic) allow the number two prescription NSAID to satisfy an FDA recommendation that NSAIDS be taken in the lowest dose for the shortest duration.
Vivlodex, the new meloxicam formulation from Iroko Pharmaceuticals for osteoarthritis, increases the surface area of meloxicam, resulting in faster absorption. According to Iroko, approximately 27 million Americans live with osteoarthritis pain, which ranges from very mild to very severe joint aches and soreness, especially with movement.
The company’s Chief Medical Officer Dr. Clarence Young notes the FDA approval of Vivlodex is important to Iroko as it continues to expand low dose NSAID options. “Research has shown that the use of NSAIDs is likely to increase as the U.S. population continues to age and experience painful conditions that are more common among older adults,” says Young. “Patients with osteoarthritis are often treated with NSAIDs for extended periods to manage their pain.”
Vivlodex, which is administered once daily at 5 or 10 mg doses, is a welcomed option for patients in need of an effective, low dose NSAID, according to Dr. Byron Cryer, Associate Dean at The University of Texas Southwestern Medical Center. “As recently as July 2015, the FDA announced they would strengthen the existing product label warnings for non-aspirin NSAIDs, further highlighting that NSAIDs should be used at the lowest effective dose for the shortest duration to potentially minimize the risk of adverse events,” says Cryer.
It important to note, Vivlodex has not shown equivalent systemic exposure to other formulations of oral meloxicam, and is not interchangeable with other formulations. For full prescribing information for Vivlodex, please visit Vivlodex.com.
Click here to read the full press release.